⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138503 | 1.00 | — | — | |
| SCHEMBL18608045 | 0.82 | — | — | |
| SCHEMBL1040192 | 0.78 | — | — | |
| SCHEMBL8718302 | 0.78 | — | — | |
| SCHEMBL1922884 | 0.78 | — | — | |
| SCHEMBL1922119 | 0.78 | — | — | |
| SCHEMBL1039456 | 0.78 | — | — | |
| SCHEMBL123550 | 0.78 | — | — | |
| SCHEMBL3104899 | 0.78 | — | — | |
| SCHEMBL1036831 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233863-B1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| CN-113679728-B | Sulfonamide compound and application thereof in preparation of drugs for treating diabetes and complications | 兰州大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-114452289-B | Application of quinoline derivatives in preparation of medicines for preventing and/or treating gastrointestinal diseases | 兰州大学 | 2023-06-09 | — | — | CN | disclosed |
| US-20230023332-A1 | OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | LUNAN PHARMACEUTICAL GROUP CORPORATION (CN) | 2023-01-26 | — | — | US | disclosed |
| CN-114729001-A | Oleane phenylpropenamide derivative and preparation method and application thereof | 鲁南制药集团股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114452289-A | Application of quinoline derivatives in preparation of drugs for preventing and/or treating gastrointestinal diseases | 兰州大学 | 2022-05-10 | — | — | CN | disclosed |
| CN-113679728-A | Sulfonamide compound and application thereof in preparing medicine for treating diabetes and complications | 兰州大学 | 2021-11-23 | — | — | CN | disclosed |
| CN-113679725-A | Cephalosporin compound and application thereof in preparation of drugs for treating diabetes and complications | 兰州大学 | 2021-11-23 | — | — | CN | disclosed |
| CN-113149993-A | Pyrrolopyrimidine derivative compound, pharmaceutical composition and application thereof | 北京普祺医药科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210171466-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AREDEA BIOSCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009018233-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009015203-A1 | NOVEL COMPOUNDS AND METHODS OF USING THEM | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080227851-A1 | LAULIMALIDE AND LAULIMALIDE ANALOGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-18 | — | — | US | disclosed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-11 | — | — | US | disclosed |